ArticleThe Journal of clinical endocrinology and metabolism2026
GH Response to Glucagon in Transition: Role of Body Mass Index and Etiology in Childhood-onset GH Deficiency.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
contextThe glucagon stimulation test (GST) is increasingly used as an alternative to the insulin tolerance test for diagnosing persistent GH deficiency (GHD) during transition, though its accuracy and appropriate cutoff values are still uncertain.
objectiveTo investigate the GH response to GST in transitional-age patients with childhood-onset GHD (CO-GHD), with a focus on the influence of body mass index (BMI) and the underlying etiology. PATIENTS AND
methodsA total of 180 patients with CO-GHD (median age 17.39 years) underwent GST. They were grouped based on the number of pituitary deficiencies and magnetic resonance imaging findings into isolated GHD (n = 80), organic moderate GHD (1-2 deficiencies with congenital or acquired anomalies, n = 63), and organic severe GHD (≥3 deficiencies with complex central nervous system abnormalities, n = 37). Additionally, patients were classified by BMI as normal weight, overweight, or obesity, according to age-appropriate BMI criteria. Childhood cancer survivors (CCS) accounted for 42% of the cohort.
resultsPeak GH response to GST showed a significant inverse association with the severity of pituitary dysfunction (P < .001) and an inverse correlation with BMI SD score (ρ = -0.46, P < .001). However, adjusting by disease group strongly reduced the impact of BMI on the GST response. When stratified by etiology or CCS status, GH peaks were primarily influenced by hypothalamic-pituitary damage with BMI showing a minimal effect.
conclusionThe GST provides valuable insights into GH deficiency in transitional-age patients with CO-GHD. GH response is primarily influenced by the severity of pituitary dysfunction, with BMI playing a minimal role once adjusted for etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.